Program
tolododekin alfa
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Skin Neoplasms, led by Ankyra Therapeutics.
Furthest: phase 1, since Nov 29, 20233 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ankyra Therapeutics | 32 open or running | phase 1since Nov 29, 2023 | Nov 29, 2023 | Apr 2027phase 1 · NCT06171750 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 29, 2023First study: phase 1 study in Skin NeoplasmsFirst studyNCT06171750 · 97 planned · United States, Canada
- Jun 11, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07027514 · 60 planned · United States
- Jul 28, 2025Phase 1 study in Cutaneous Squamous Cell Carcinoma (CSCC)NCT07100925
Ahead
- Apr 2027Primary completion: phase 1 study in Skin NeoplasmsNCT06171750
- Jun 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07027514
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07100925Cutaneous Squamous Cell Carcinoma (CSCC) | 1 | Withdrawn | Jun 2030 | 0 |
| NCT07027514Carcinoma, Non-Small-Cell Lung · United States | 1 | Recruiting | Jun 30, 2027 | 60 |
| NCT06171750Skin Neoplasms · United States, Canada | 1 | Recruiting | Apr 2027 | 97 |
How it is read
Names in the registry
- “tolododekin alfa”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
- Skin Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.